
Pfizer’s TUKYSA Regimen Wins FDA Approval for Front-Line Maintenance in HER2+ Metastatic Breast Cancer
FDA Approves Pfizer’s TUKYSA Regimen for First-Line Maintenance in HER2+ Metastatic Breast Cancer Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved TUKYSA® (tucatinib) in combination…













